Blog

DEEP RESEARCH · HANALL BIOPHARMA

HanAll Biopharma: FcRn Pivot and the Hybrid Business Model

How the strategy shifts from batoclimab to imeroprubart while the pharma business funds R&D time

Date: 2025-11-29 · Immunology pipeline/company analysis · Naver Blog source and attached references

You are responsible for your own investment decisions. This material is research, not a recommendation to buy or sell.

0. Bottom line first

HanAll’s key feature is the combination of traditional-pharma cash flow and global-biotech pipeline optionality. The FcRn platform is shifting from batoclimab toward imeroprubart (IMVT-1402), and if that transition works, the company’s profile can change materially.

HanAll hybrid modelDomestic pharma business + global licensing
Cash cowBiotop · Eligard · Normix
FcRnBatoclimab · imeroprubart
Follow-onsTanfanercept · HL192
PartnersImmunovant · Roivant
The base business buys R&D time, while partnerships spread global clinical costs.

1. Company evolution

Official fact: The source says HanAll began as Sunkyung Pharmaceutical in 1973, supplied more than 160 ETC/OTC products over 52 years, changed its name to HanAll Biopharma in 2010, and accelerated innovative-drug development after joining the Daewoong group in 2015.

Interpretation: Unlike a pure biotech, HanAll’s pharma business buffers R&D funding. That lowers the risk that every clinical delay immediately becomes a dilution event.

2. FcRn platform: from first generation to second

The largest strategic shift highlighted in the source is the move from batoclimab to imeroprubart (IMVT-1402). This is framed not as a simple candidate replacement but as a pivot toward a potential best-in-class position in autoimmune disease.

1st gen

Batoclimab

The foundational candidate that demonstrated the FcRn platform’s clinical potential.

2nd gen

Imeroprubart

The new strategic focus, aiming for improved safety and efficacy.

Market

Autoimmune disease

Immunology is one of the major global prescription-drug growth engines alongside GLP-1 therapies.

3. Business model and financial snapshot

Official fact: The source says 3Q 2025 pharmaceutical revenue grew 12% year over year. It also cites the 2017 Immunovant/Roivant licensing deal at USD 502.5 million total value with double-digit royalties upon commercialization.

Item3Q 20253Q 2024Change
RevenueKRW 40.8bnKRW 36.8bn+11%
Pharma revenueKRW 35.5bnKRW 31.8bn+12%
Licensing revenueKRW 1.5bnKRW 2.2bn-32%
Operating profitKRW 0.35bnKRW 0.43bn-19%
Net incomeKRW 0.30bnKRW 0.22bn+35%
Recurring R&D expenseKRW 4.8bnKRW 5.9bn-20%

4. Risks and watch points

  • Immunovant schedule changes can delay data readouts.
  • The Harbour BioMed legal dispute remains a China-rights and partnership risk.
  • Imeroprubart must prove differentiated safety and efficacy versus competing FcRn drugs.
  • Because licensing revenue is volatile, pharma-business growth is the defensive line.

5. My core judgment

I see HanAll as more complex than a pure biotech. Looking only at near-term earnings misses pipeline value; looking only at pipeline upside can understate the base business. Imeroprubart data after 2026 is the key factor that can tilt that balance.

Sources

Naver original